Transgene Announces Financial Calendar for 2020
STRASBOURG, France--(BUSINESS WIRE)--Dec 18, 2019--
Transgene (Paris:TNG) (Euronext Paris: TNG) today announced its financial reporting dates for 2020:
March 11, 2020: 2019 Fiscal Year Results
May 6, 2020: First Quarter 2020 Financial Results
May 27, 2020: Annual Shareholders’ Meeting
September 16, 2020: First Half 2020 Financial Results
November 5, 2020: Third Quarter 2020 Financial Results
Transgene (Euronext: TNG) is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s clinical-stage programs include TG4001, a therapeutic vaccine against HPV-positive cancers and TG6002, an oncolytic virus for the treatment of solid tumors.
With its proprietary platform Invir.IO®, Transgene builds on its expertise in viral vectors engineering to design a new generation of multifunctional oncolytic viruses. myvac ™, an individualized MVA-based immunotherapy platform designed to integrate neoantigens, completes this innovative research portfolio. TG4050, the first candidate selected from the myvac ™ platform, is entering the clinic for the treatment of ovarian cancer and head and neck cancer.
Additional information about Transgene is available at: www.transgene.fr.
Follow us on Twitter: @TransgeneSA
View source version on businesswire.com:https://www.businesswire.com/news/home/20191218005538/en/
Jean-Philippe Del/Lucie Larguier
+33 (0)3 88 27 91 04
Citigate Dewe Rogerson
David Dible/Sylvie Berrebi
+44 (0)20 7638 9571
KEYWORD: EUROPE UNITED STATES NORTH AMERICA FRANCE
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH FINANCE OTHER HEALTH PHARMACEUTICAL PROFESSIONAL SERVICES STEM CELLS ONCOLOGY RESEARCH INFECTIOUS DISEASES HOSPITALS GENETICS SCIENCE CLINICAL TRIALS
Copyright Business Wire 2019.
PUB: 12/18/2019 12:00 PM/DISC: 12/18/2019 12:01 PM